Table 1:

Clinical trials investigating PET at various time points and with various PET radiopharmaceuticals in melanoma patients treated with different IO therapeutics as registered at www.clinicaltrials.gov at the time of submission.

Study ID	Radiopharmaceutical(s)	IO Therapy	Primary endpoint	Imaging Time points
NCT03356470	FDG and FLT	Nivolumab or Pembrolizumab	Correlate baseline and posttreatment molecular imaging biomarkers of response to immunotherapy	Baseline and 1012 weeks posttherapy
NCT03089606	FDG and [11C]AMT	Pembrolizumab	Association of SUVmax with objective response rate	Baseline and 12 weeks posttherapy
NCT03888950	FDG	Nivolumab or Pembrolizumab	Quantify changes in FDG uptake by PERCIST criteria	Baseline , day 21- 31, and 3 months post-therapy
NCT04272658	FDG	Nivolumab or Pembrolizumab or combo Ipilimumab/Nivoluma b	Differentiate progression vs pseudoprogressio n using 4D bodyto-whole dynamic acquisition	Not specifie d
NCT03584334	FDG	Nivolumab or Pembrolizumab	Threshold of FDG retention index to distinguish progression versus pseudoprogression	Baseline , 7 weeks, and 3 months posttherapy
NCT02716077	FDG	Pembrolizumab	Disease-free survival	Not specifie d
NCT04221438	FLT	Encorafenib and Binimetinib	Change in SUVmax	Baseline and 8–9 weeks posttherapy
NCT04462406	FDG	Nivolumab or Pembrolizumab or combo with	Event-free survival – active surveillance	Baseline and 12 months
		Ipilimumab	following negative PET or positive PET but negative biopsy	posttherapy
NCT03520634	[18F]PD-L1	Nivolumab	Determine optimal dose of tracer and timing of imaging	Baseline and 6 weeks posttherapy
NCT02591654	FLT	Pembrolizumab	Prevalence of lesion detection	Baseline and 6 weeks posttherapy